| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| HRTX | HRTX | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| HRTX | HRTX | Shares | USD | XNCM |
Heron Therapeutics, Inc. develops and commercializes therapies for acute care and oncology patients. Its product portfolio includes SUSTOL® for chemotherapy-induced nausea and vomiting, CINVANTI® for chemotherapy-induced nausea and vomiting, ZYNRELEF® for postoperative pain management, and APONVIE® for postoperative nausea and vomiting. The company focuses on addressing unmet medical needs through its patented technologies and drug development efforts.
No recent RNS announcements for HRTX across HRTX.
No recent RNS announcements for HRTX across HRTX.